Join The Discussion

 

Bridge collapse on I-35 north of Austin

SALADO, Texas (AP) — Emergency crews are responding to a reported bridge collapse along an interstate in Central Texas.

read more >

Amazon begins Prime Now program in Dallas area

If you just have to have it now, as in one hour, you can, at least in the Dallas area, as Amazon.com Inc. announced Thursday it will offer Prime Now.

read more >

Monty Bennett: Businessman, water district activist

Monty Bennett’s name will not appear on the ballot for the Tarrant Regional Water District board of directors yet he remains a powerful backstage player whose influence could shape the direction of the district’s business for years to come.

read more >

Price appeal: Condos going up on Near Southside

Chris Brassard and Omar Diaz had apartments in mind when they built a 12-unit complex on May Street just south of West Magnolia Avenue on Fort Worth’s Near Southside. Then their leasing agent, Will Northern of Northern Realty Group, suggested they consider selling the units as condominiums.

read more >

Westchester Plaza manager says "business as usual" for now

The future of a redevelopment plan for the 50-year-old Westchester Plaza on Fort Worth's Near Southside is unclear.

read more >

 

Former TECH Fort Worth client raises $107M in IPO

ZS Pharma Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, raised nearly $107 million on the NASDAQ capital market from its initial public offering on June 18.
ZS Pharma, a Texas Emerging Technology Fund awardee based in Coppell, also granted the underwriters a 30-day option to purchase up to an additional 891,667 shares of common stock at the IPO price, less underwriting discounts and commissions. The offering is expected to close on or about June 23, subject to customary closing conditions.


ZS Pharma received a $2 million TETF award in 2010 for its development of an orally available sorbent product, ZS-9, which was designed to remove excess potassium from the blood and maintain normal potassium levels. This technology could potentially be used to treat hyperkalemia, a condition that can lead to irregular heartbeat and sudden cardiac death. ZS Pharma was a client of TECH Fort Worth.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the IPO. BMO Capital Markets Corp. is lead manager and William Blair & Co. LLC is co-manager.
ZS Pharma Inc. is traded under the symbol ZSPH.

Betty Dillard
bdillard@bizpress.net


 

< back

Email   email
hide
Catch
How 'bout them Cowboys?